Q1 2024 Holdings
Filed 2024-05-15 | 52 holdings | $458.9M | 13F-HR/A | View on SEC ↗ · Holdings Table ↗
Amended (2024-05-29) | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Ocular Therapeutix Inc(OCUL) | COM | 67576A100 | $60.5M | 6,653,138 | 13.2% |
| Harrow Health Inc(HROW) | COM | 415858109 | $51.9M | 3,920,600 | 11.3% |
| TG Therapeutics Inc(TGTX) | COM | 88322Q108 | $34.7M | 2,280,000 | 7.6% |
| Keros Therapeutics Inc(KROS) | COM | 492327101 | $24.3M | 367,500 | 5.3% |
| Rhythm Pharmaceuticals Inc(RYTM) | COM | 76243J105 | $22.3M | 515,000 | 4.9% |
| Catalyst Pharmaceuticals Inc(CPRX) | COM | 14888U101 | $16.0M | 1,004,355 | 3.5% |
| Arvinas Inc(ARVN) | COM | 04335A105 | $13.6M | 330,000 | 3.0% |
| Iovance Biotherapeutics Inc(IOVA) | COM | 462260100 | $13.3M | 897,000 | 2.9% |
| Jasper Therapeutics Inc(JSPR) | COM NEW | 471871202 | $12.8M | 435,573 | 2.8% |
| Edgewise Therapeutics Inc(EWTX) | COM | 28036F105 | $12.1M | 665,000 | 2.6% |
| Applied Therapeutics(APLT)A | COM | 03828A101 | $12.0M | 1,770,000 | 2.6% |
| 4D Molecular Therapeutics Inc(FDMT) | COM | 35104E100 | $11.0M | 344,123 | 2.4% |
| Codexis Inc(CDXS) | COM | 192005106 | $10.9M | 3,120,000 | 2.4% |
| Protara Therapeutics Inc(TARA) | COM STK | 74365U107 | $10.8M | 2,692,594 | 2.4% |
| Acelyrin Inc | COM | 00445A100 | $10.7M | 1,580,000 | 2.3% |
| Crinetics Pharmaceuticals Inc(CRNX)A | COM | 22663K107 | $9.8M | 210,000 | 2.1% |
| Eton Pharmaceuticals Inc(ETON) | COM | 29772L108 | $9.2M | 2,445,781 | 2.0% |
| Trevi Therapeutics Inc(TRVI) | COM | 89532M101 | $9.1M | 2,645,000 | 2.0% |
| Lyell Immunopharma Inc | COM | 55083R104 | $7.5M | 3,355,000 | 1.6% |
| Newamsterdam Pharma Company(NAMS) | ORDINARY SHARES | N62509109 | $7.5M | 315,388 | 1.6% |
| Ventyx Biosciences Inc(VTYX) | COM | 92332V107 | $7.1M | 1,285,000 | 1.5% |
| Intellia Therapeutics Inc(NTLA) | COM | 45826J105 | $7.0M | 255,000 | 1.5% |
| Compass Therapeutics Inc(CMPX) | COM | 20454B104 | $6.3M | 3,170,000 | 1.4% |
| Xoma Corp del(XOMA) | COM NEW | 98419J206 | $6.0M | 250,000 | 1.3% |
| Liquidia Corporation(LQDA) | COM NEW | 53635D202 | $5.8M | 395,000 | 1.3% |
| Vaxcyte Inc(PCVX) | COM | 92243G108 | $5.8M | 85,000 | 1.3% |
| Nyxoah S A(NYXH) | SHS | B6S7WD106 | $4.3M | 320,000 | 0.9% |
| Savara Inc(SVRA) | COM | 805111101 | $4.3M | 855,000 | 0.9% |
| Syros Pharmaceuticals Inc(SYRS) | COM NEW | 87184Q206 | $4.2M | 787,545 | 0.9% |
| Urogen Pharma LTD(URGN) | COM | M96088105 | $4.1M | 270,000 | 0.9% |
| Nurix Therapeutics Inc(NRIX)A | 67080M103 | 67080M103 | $3.9M | 267,210 | 0.9% |
| Revance Therapeutics Inc(RVNCEUR) | COM | 761330109 | $3.9M | 785,000 | 0.8% |
| Relmada Therapeutics Inc(RLMD) | COM | 75955J402 | $3.5M | 759,000 | 0.8% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $3.3M | 112,700 | 0.7% |
| Gossamer BIO Inc | NOTE 5.000% 6/0 | 38341PAA0 | $3.2M | $8,000,000 | 0.7% |
| Zentalis Pharmaceuticals Inc(ZNTL) | COM | 98943L107 | $3.2M | 200,000 | 0.7% |
| Allakos Inc(ALLKGUSD) | COM | 01671P100 | $3.1M | 2,435,000 | 0.7% |
| Gossamer BIO Inc(GOSS) | COM | 38341P102 | $2.9M | 2,440,109 | 0.6% |
| Ibio Inc(IBIO) | COM NEW | 451033708 | $2.8M | 680,000 | 0.6% |
| Verastem Inc(VSTM) | COM NEW | 92337C203 | $2.5M | 211,400 | 0.5% |
| Aligos Therapeutics Inc | COM | 01626L105 | $1.6M | 1,630,000 | 0.3% |
| Context Therapeutics Inc(CNTX) | COM | 21077P108 | $1.5M | 1,108,357 | 0.3% |
| Precigen Inc(PGEN) | COM | 74017N105 | $1.4M | 947,500 | 0.3% |
| Larimar Therapeutics Inc(LRMR) | COM | 517125100 | $1.3M | 174,413 | 0.3% |
| Fulcrum Therapeutics Inc(FULC) | COM | 359616109 | $1.2M | 130,000 | 0.3% |
| Morphosys AG | SPONSORED ADS | 617760202 | $1.2M | 65,000 | 0.3% |
| Glaukos Corp(GKOS) | COM | 377322102 | $808.6K | 8,576 | 0.2% |
| PMV Pharmaceuticals Inc(PMVP) | COM | 69353Y103 | $802.1K | 471,481 | 0.2% |
| Biodesix | COM | 09075X108 | $764.6K | 534,657 | 0.2% |
| Regulus Therapeutics Inc(RGLS) | COM | 75915K309 | $490.5K | 170,308 | 0.1% |